On December 1, 2020, EVerZom (http://www.everzom.com), a biopharmaceutical company specialized in the bioproduction of exosomes and headquartered in Paris, France, announced that it has raised €1.1 million (~$1.48 million) in funding from institutional and private investors to develop its exosome bioproduction platform. This funding will speed up the platform development and scale-up, with the objective to allow routine clinical grade production by 2022. Exosomes are biological nanoparticles released by cells as an intercellular communication system to transport biomolecules. Exosomes have the ability to deliver therapeutics or regenerate tissue in several pathologies, including osteoarthritis, heart failure, and liver and kidney diseases, conditions which impact more than 150 million patients worldwide. Exosomes are now considered one of the safest and most promising future regenerative therapy solutions. They are also easy to store and have a low immunogenic profile, thus reinforcing their potential. Increasingly, academic and industrial players are working on the therapeutic potential of exosomes. The main obstacle to the translation of exosomes into clinical development is industrial manufacturing, while maintaining robust quality and reproducibility. EVerZom's proprietary innovation consists in applying turbulence stimulation on cells to trigger massive exosome release. This approach enables the production of ten times more exosomes ten times more rapidly than classical methods. The technology is being developed and already implemented in GMP-certified systems, simplifying the clinical transfer. This technology and the know-how developed around exosomes allows EVerZom to offer a scalable and reproducible exosome production process with robust quality controls.
Login Or Register To Read Full Story